Kite Pharma, Inc. (KITE) Expected to Earn Q1 2018 Earnings of ($2.26) Per Share
Kite Pharma, Inc. (NASDAQ:KITE) – SunTrust Banks issued their Q1 2018 earnings per share (EPS) estimates for Kite Pharma in a research report issued to clients and investors on Tuesday. SunTrust Banks analyst P. Lawson expects that the biopharmaceutical company will earn ($2.26) per share for the quarter. SunTrust Banks also issued estimates for Kite Pharma’s Q2 2018 earnings at ($2.26) EPS, Q3 2018 earnings at ($2.21) EPS, Q4 2018 earnings at ($1.96) EPS and FY2020 earnings at $0.99 EPS.
A number of other equities research analysts have also recently commented on KITE. Vetr cut Kite Pharma from a “buy” rating to a “hold” rating and set a $83.76 target price on the stock. in a research note on Monday, April 17th. Jefferies Group LLC reissued a “buy” rating on shares of Kite Pharma in a research note on Thursday, April 20th. Canaccord Genuity set a $90.00 target price on Kite Pharma and gave the stock a “buy” rating in a research note on Thursday, April 20th. UBS AG cut Kite Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, May 8th. Finally, Raymond James Financial, Inc. reissued a “mkt perform” rating on shares of Kite Pharma in a research note on Monday, May 8th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $87.66.
Shares of Kite Pharma (NASDAQ:KITE) traded down 0.13% during trading on Wednesday, reaching $119.97. The company’s stock had a trading volume of 537,086 shares. Kite Pharma has a one year low of $39.82 and a one year high of $120.78. The stock’s 50 day moving average is $103.84 and its 200 day moving average is $79.27. The firm’s market cap is $6.78 billion.
Kite Pharma (NASDAQ:KITE) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, beating the consensus estimate of ($1.97) by $0.03. Kite Pharma had a negative return on equity of 55.80% and a negative net margin of 1,166.54%. The business had revenue of $10.10 million for the quarter, compared to analysts’ expectations of $9.59 million. During the same period last year, the business earned ($0.91) EPS. The business’s revenue was up 110.4% on a year-over-year basis.
In other Kite Pharma news, COO Cynthia M. Butitta sold 10,000 shares of the company’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $88.55, for a total value of $885,500.00. Following the completion of the sale, the chief operating officer now owns 127,795 shares in the company, valued at $11,316,247.25. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Timothy L. Moore sold 6,000 shares of the company’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $110.06, for a total value of $660,360.00. Following the completion of the sale, the executive vice president now owns 55,400 shares of the company’s stock, valued at approximately $6,097,324. The disclosure for this sale can be found here. In the last 90 days, insiders sold 165,099 shares of company stock valued at $16,244,448. Company insiders own 14.00% of the company’s stock.
A number of hedge funds have recently modified their holdings of the company. Winslow Evans & Crocker Inc. acquired a new stake in Kite Pharma during the second quarter valued at about $124,000. Baillie Gifford & Co. acquired a new stake in Kite Pharma during the first quarter valued at about $201,000. Comerica Bank acquired a new stake in Kite Pharma during the second quarter valued at about $201,000. Turner Investments LLC acquired a new stake in Kite Pharma during the first quarter valued at about $235,000. Finally, Capital Investment Advisory Services LLC acquired a new stake in Kite Pharma during the second quarter valued at about $238,000. Institutional investors and hedge funds own 84.96% of the company’s stock.
About Kite Pharma
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.